Is Nymox Pharmaceutical Corp. (NASDAQ:NYMX) rough on the edges?


Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is based in St Laurent, Canada.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has been in the news for all the right reasons.

Nymox Pharmaceutical advanced 11.56% to close at $3.57 on Wednesday. The stock traded within a one dollar range at $4.10 and $3.15 on volume of 1.86 million shares traded. The company is expected to begin the process of submitting its initial filing that will seek approval for Fexapotide Triflutate, its BPH drug, in the next few weeks. On March 29th, Nymox Director James Robinson who regularly purchased shares of the company in last couple of years, purchased another 50,000 shares of the company at prices ranging from $3.49 to $3.60 per share. He now owns 3,317,950 shares of the company.

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is all set to announce its earnings on May 15. As per Zack’s analyst ratings, Nymox Pharmaceutical Corporation (NASDAQ:NYMX) currently has an average brokerage rating of . On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:NYMX) is $ with a high of $ and a low of $.

The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 57.50 suggesting a bullish price action.

The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). Currently, the 5 day EMA 4.67 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 3.97 is lower than current trading price depicting a bullish signal..

As such, while we believe Nymox Pharmaceutical Corporation (NASDAQ:NYMX) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.